admin, Author at PsyNews.com

Home Authors Posts by admin

2176 POSTS 0 COMMENTS

https://psynews.com

Wesana Announces Second Quarter 2022 Financial Results

Psychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops...

MindMed Completes 1-for-15 Reverse Share Split

PT350 – Jim Gilligan – Psilocybin and Accessing the “Off” Switch...

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120...

Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional...

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120...

FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY...

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic...

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction...

1...125126127...218 Page 126 of 218

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin

Wesana Announces Second Quarter 2022 Financial Results

Psychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops...

MindMed Completes 1-for-15 Reverse Share Split

PT350 – Jim Gilligan – Psilocybin and Accessing the “Off” Switch...

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120...

Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional...

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120...

FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY...

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic...

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction...

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY